Re: SURUSS trial
From: Terry J DuBose (tjdubose@juno.com)
Mon May 14 07:26:18 2001
Dr. Bui, thank you for this information.
--
Terry J DuBose
On Mon, 14 May 2001 06:42:13 -0500 The-Hung Bui <The-Hung.Bui@ks.se>
writes:
> At 18:43 2001-05-13 -0500, you wrote:
> >Bryan, do you know where it will be published? 50,000
> pregnancies...
> >can't wait to see that... is there a published description of the
> trial
> >protocol anywhere?
> >
> >Thanks for the heads-up. Please let us know when more information
> is
> >available.
> >
> >Thanks, Terry J DuBose
> >
> >---------------------------------------
> >
> >---------------------------------------
> >On Sun, 13 May 2001 16:37:50 -0500 "Bryan Beattie"
> >---------------------------------------
> ><bbeattie@globalnet.co.uk> writes:
> > > THE UK SURUSS TRIAL IS COMPLETE AND IS SIMILAR TO THE FASTER
> TRIAL
> > > BASED ON 50,000 PREGNANCIES. IT SHOULD BE PUBLISHED IN NEXT FEWW
> > > MONTHS. PRINCIPLE INVESTIGATOR PROF NICK WALD, LONDON.
>
> Terry,
> See below. A special report will be in Health Technology Assessment,
> but it
> will surely be published also in a renown journal.
>
> Project title: SURUSS (serum, urine and ultrasound screening study)
> Project
> code: 93/25/05 Cost: £864,443 Grantholder: Professor Nick Wald, Head
> of
> Department, Dept of Environmental & Preventive Medicine, St Barts
> and the
> London Medical School Start date: June 1996 Estimated publication
> date: Mid
> 2001* *Please note that HTA publication dates include an estimate of
> time
> needed for report preparation and printing based on experience from
> the
> first year of publication
> Abstract:
> This is a national, observational study of first and second
> trimester Downs
> syndrome screening invovling 52,000 women recruited from 15 centres,
>
> yielding an expected 73 term pregnancies with Downs syndrome (or
> about 130
> at 12 weeks). The study will assess the individual and combined
> performance
> of serum, urine and ultrasound markers in the first trimester of
> pregnancy.
> Performance will be directly compared between first and second
> trimester
> markers in the same women to identify the most effective screening
> method.
> Ultrasound nuchal translucency measurements will be taken at 10-12
> weeks
> and serum and urine samples collected at this time and also at the
> time of
> routine screening (about 16 weeks). The samples will be stored for
> analysis
> at the end of the study. The size of this study and its
> observational
> design will ensure that the estimates of screening performance will
> be
> precise and unbiased. The study will specify the organisational
> arrangements necessary for the implementation of the most effective
> screening method.
>
> *****************************************************************
> The-Hung Bui, M.D.
> Senior Consultant
> Director, Fetal Diagnosis Programme
> Department of Molecular Medicine
> Clinical Genetics Unit
> Karolinska Hospital
> S-171 76 Stockholm, Sweden
>
> phone: +46 8 517 74989 or 517 72472 (secretary)
> fax: +46 8 32 77 34
> E-mail: The-Hung.Bui@ks.se
> ******************************************************************
________________________________________________________________
GET INTERNET ACCESS FROM JUNO!
